Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database
This study used the FAERS database to identify frequently reported ADEs associated with pembrolizumab in the treatment of EC, including endocrine system diseases, musculoskeletal system disorders, skin and subcutaneous tissue reactions, and hepatotoxicity. These findings provide crucial evidence for risk stratification and safety monitoring in clinical practice, emphasizing the need for vigilance toward specific organ systems during the 0-30-day treatment window.
Authors
- Huiping Zhang (ORCID: https://orcid.org/0000-0002-9003-0996)
- Zhuo Zhou (ORCID: https://orcid.org/0000-0001-5862-9854)
- Yu Dai (ORCID: https://orcid.org/0000-0003-3534-0745)
- Man Di (ORCID: https://orcid.org/0000-0001-7789-387X)
- Shan Wang (ORCID: https://orcid.org/0000-0003-3396-5936)
- Jing-Jing Huang
- Jingjing Wang (ORCID: https://orcid.org/0009-0001-5376-8836)
Institutions
- Northwest University (CN)
- Tang Du Hospital (CN)
- First Hospital of Xi'an (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fphar.2025.1622339
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05